Risk of Thromboembolism With Eltrombopag: A Case Report of Deep Vein Thrombosis and Bilateral Pulmonary Embolism. 

 -  2023 
<br/><br/> Eltrombopag is a second-line therapy for refractory thrombocytopenia from immune thrombocytopenic purpura (ITP). The medication is generally well tolerated but can lead to adverse thromboembolic complications in rare instances. We present a case of lower extremity deep vein thrombosis with bilateral pulmonary embolism in an ITP patient receiving eltrombopag. The patient underwent catheter-directed thrombolysis for pulmonary embolism. Eltrombopag was stopped on discharge, considering the potential cause of venous thrombosis. Copyright © 2023, Ghumman et al. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>2168-8184 
<br/><br/><label>Standard No.: </label>10.7759/cureus.33615 [doi] PMC9911261 [pmc] 
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Union Memorial Hospital
<br/><br/><label>Index Terms--Occupation: </label><br/>Internal Medicine Residency
<br/><br/><label>Index Terms--Function: </label><br/>Case Reports